Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.55, marking a +1.15% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.32%.

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

An intrinsic value evaluation of Vertex Pharmaceuticals' current CF portfolio shows the share price is undervalued by at least 30%. See here why I consider the VRTX stock a long position.

Vertex Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy). Digging into valuation, Vertex Pharmaceuticals currently has a Forward P/E ratio of 17.49.

Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.11, moving +0.44% from the previous trading session. This move lagged the S&P 500's daily gain of 0.91%. At the same time ...